SMS Lifesciences India Ltd
Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]
- Market Cap ₹ 305 Cr.
- Current Price ₹ 1,008
- High / Low ₹ 1,750 / 487
- Stock P/E 15.0
- Book Value ₹ 621
- Dividend Yield 0.15 %
- ROCE 6.89 %
- ROE 3.66 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of -4.13% over past five years.
- Company has a low return on equity of 6.75% over last 3 years.
- Dividend payout has been low at 3.58% of profits over last 3 years
- Debtor days have increased from 49.9 to 61.3 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
378 | 261 | 266 | 350 | 316 | 306 | 333 | |
343 | 235 | 235 | 316 | 287 | 275 | 288 | |
Operating Profit | 35 | 25 | 30 | 35 | 29 | 31 | 46 |
OPM % | 9% | 10% | 11% | 10% | 9% | 10% | 14% |
2 | 2 | 2 | 14 | 5 | 4 | 5 | |
Interest | 6 | 5 | 5 | 6 | 7 | 10 | 10 |
Depreciation | 6 | 8 | 8 | 10 | 11 | 15 | 15 |
Profit before tax | 25 | 15 | 20 | 33 | 17 | 10 | 26 |
Tax % | 30% | 31% | 31% | 23% | 31% | 36% | |
18 | 10 | 14 | 25 | 11 | 6 | 21 | |
EPS in Rs | 59.04 | 33.67 | 44.85 | 83.75 | 37.91 | 30.07 | 72.34 |
Dividend Payout % | 3% | 0% | 3% | 2% | 4% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -4% |
3 Years: | 5% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -19% |
3 Years: | -22% |
TTM: | 722% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 29% |
3 Years: | 5% |
1 Year: | 95% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 7% |
Last Year: | 4% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Reserves | 103 | 113 | 126 | 149 | 166 | 174 | 185 |
47 | 65 | 65 | 80 | 100 | 101 | 92 | |
116 | 72 | 108 | 125 | 126 | 113 | 111 | |
Total Liabilities | 270 | 253 | 302 | 357 | 395 | 391 | 391 |
118 | 124 | 130 | 142 | 228 | 223 | 217 | |
CWIP | 3 | 16 | 38 | 51 | 1 | 6 | 13 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
148 | 113 | 134 | 164 | 166 | 161 | 161 | |
Total Assets | 270 | 253 | 302 | 357 | 395 | 391 | 391 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
30 | 15 | 35 | -11 | 15 | 24 | |
-44 | -27 | -26 | -7 | -31 | -18 | |
15 | 12 | -3 | 11 | 17 | -7 | |
Net Cash Flow | 1 | -0 | 6 | -8 | 0 | -1 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 40 | 30 | 47 | 35 | 53 | 61 |
Inventory Days | 116 | 149 | 164 | 159 | 184 | 196 |
Days Payable | 140 | 101 | 163 | 146 | 127 | 143 |
Cash Conversion Cycle | 16 | 78 | 48 | 48 | 110 | 115 |
Working Capital Days | 27 | 47 | 37 | 56 | 76 | 89 |
ROCE % | 12% | 13% | 12% | 8% | 7% |
Documents
Announcements
- Newspaper Publication (Financial Results) 15 Nov
-
Board Meeting Outcome for 91St Board Meeting
13 Nov - Board approved financial results and proposed name change.
-
Board Meeting Intimation for Meeting Scheduled To Be Held On Nov 13, 2024
8 Nov - 91st Board meeting to discuss financial results.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 14 Oct
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 10 Oct
Business Overview:[1][2][3]
Company is the demerged entity of SMS Pharmaceuticals Ltd, catering to semi-regulated markets across India, Europe, and Asia with a portfolio of 12 APIs in the GAS and Anti-erectile dysfunction (EDF) therapeutic segment. It does manufacturing of Antiulcerative products, for Indian and global markets and supplies KSMs and Intermediates